Alicia Morgans, MD, MPH

Articles

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

September 24th 2024

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18th 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Morgans on Considerations for Treating nmCRPC in the Community Setting

August 22nd 2024

Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25th 2024

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

July 19th 2024

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Prostate Cancer Management: Future Directions in Care

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Addressing Bone and Visceral Metastases in Metastatic CRPC

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

May 18th 2022

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

Selecting Among Novel Imaging Options in Metastatic CRPC

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Utility of Imaging as a Biomarker

May 11th 2022

Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.

DNA Alterations and Selection of PARP Inhibitors in mCRPC

May 4th 2022

Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

Overview of Therapy for mCRPC: PARP Inhibitors

May 4th 2022

A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.

Interpreting Data From the ARASENS Trial in Metastatic HSPC

April 27th 2022

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

April 27th 2022

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.

Role of Micronized Abiraterone in Metastatic HSPC

April 20th 2022

Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.

Overview of Treatment for Metastatic HSPC

April 20th 2022

Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.

Monitoring Strategies in Nonmetastatic CRPC

April 13th 2022

A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].

Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures

April 13th 2022

A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC

April 6th 2022

Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.